Analysing CTCs and ctDNA in patients with CRC allows us to choose the best therapy with respect to the tumour mutations identified: presence of RAS mutations, Anti-Epidermal Growth Factor Receptor (anti-EGFR) mutations, and BRAF mutations. The gene discussed is BRAF; the disease is colorectal carcinoma.